Arbutus plans US$230 million Dutch auction tender offer for its shares

The terms

Arbutus Biopharma Corporation (Nasdaq: ABUS) said on August 21, 2026 that it intends to repurchase up to US$230 million of its common shares through a modified "Dutch Auction" tender offer. The release gives a purchase price of not less than US$5.00 and not more than US$5.75 per share, paid in cash, less any applicable withholding taxes and without interest. The release does not say how many shares the offer would cover at those prices.

The company expects the offer to commence on or about August 24, 2026 and, unless it is extended or terminated, to expire on or about September 29, 2026. Arbutus expects to fund it from cash on hand.

The release says the offer "has not yet been commenced" and that "there can be no assurance that Arbutus will commence the Offer on the terms described herein or at all." It depends on exemptive relief under securities laws in Canada and the United States covering a proportionate tender feature and certain extension requirements. Arbutus says it has applied for that relief and expects to start the offer promptly after receiving it. The release gives no date for that decision.

Who is involved

J.P. Morgan Securities LLC will act as dealer-manager for the offer. Georgeson LLC will be the information agent, and TSX Trust Company will be the depositary. The release says shareholders are urged to read the tender offer statement on Schedule TO and the Canadian offer documents once they are filed, because they will contain the full terms. Those documents had not yet been filed when the release came out.

Chief Executive Officer Lindsay Androski tied the offer to the company's March 2026 settlement with Moderna and to the initial payment under it, which the company received in July 2026. In her words, the company is "thrilled to announce our intention to return the financial proceeds" to shareholders who, she said, stood by the company through a long process. The release says Arbutus and its exclusive licensee, Genevant Sciences, will keep enforcing their patents against Pfizer and BioNTech.

What the company has and what it owes

The company ties the buyback to the settlement payment, but says it will be funded from cash on hand. The 10-K filed March 23, 2026 reports total cash, cash equivalents and marketable securities of $91.5 million at December 31, 2025, with no outstanding debt. Of that, $18.0 million was cash and cash equivalents and $73.5 million was investments. XBRL figures give cash and cash equivalents of $19.2 million at June 30, 2026, with short-term investments of $73.5 million. The Moderna payment came after that date.

The same 10-K reports a net loss of $33.5 million for 2025, down from $69.9 million in 2024, and cash used in operations of $39.6 million, down from $64.8 million. Revenue was $14.1 million for 2025 and $6.2 million for 2024. The company ceased discovery work, halted preparations for a potential IM-PROVE III clinical trial and cut its workforce in 2025, and it planned to exit its Warminster, Pennsylvania headquarters.

The company also owes former Enantigen shareholders up to $102.5 million in sales performance milestones tied to a first commercialized hepatitis B product, plus a royalty capped at $1.0 million. That obligation sits alongside the buyback.

The open questions

Arbutus is developing imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101, for chronic hepatitis B infection. The 10-K calls the November 2024 IM-PROVE I results with imdusiran positive, but it also reports that preparations for a potential IM-PROVE III trial were halted.

The buyback would return money that came from a one-time legal settlement, not from a drug approval or a licensed product. It would also leave the company with less of the cash it has. The company still reports losses in the 10-K, and the offer is not yet open.

Report an error

Companies in this story

ABUSArbutus Biopharma CorporationNASDAQ · United StatesOpen the starter desk